Shanghai Pharmaceuticals Holding Stock Revenue
| SHPMY Stock | USD 8.20 0.32 4.06% |
Shanghai Pharmaceuticals Holding fundamentals help investors to digest information that contributes to Shanghai Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Shanghai Pink Sheet. The fundamental analysis module provides a way to measure Shanghai Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shanghai Pharmaceuticals pink sheet.
Shanghai |
Shanghai Pharmaceuticals Holding Company Revenue Analysis
Shanghai Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Shanghai Pharmaceuticals Revenue | 215.82 B |
Most of Shanghai Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Pharmaceuticals Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Shanghai Pharmaceuticals Holding reported 215.82 B of revenue. This is much higher than that of the Healthcare sector and 170.75% higher than that of the Medical Distribution industry. The revenue for all United States stocks is significantly lower than that of the firm.
Shanghai Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Shanghai Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Shanghai Pharmaceuticals by comparing valuation metrics of similar companies.Shanghai Pharmaceuticals is currently under evaluation in revenue category among its peers.
Shanghai Fundamentals
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0281 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 9.42 B | |||
| Shares Outstanding | 739.51 M | |||
| Price To Earning | 5.42 X | |||
| Price To Book | 0.69 X | |||
| Price To Sales | 0.04 X | |||
| Revenue | 215.82 B | |||
| Gross Profit | 28.41 B | |||
| EBITDA | 10.73 B | |||
| Net Income | 5.09 B | |||
| Cash And Equivalents | 37.3 B | |||
| Cash Per Share | 50.45 X | |||
| Total Debt | 7.16 B | |||
| Debt To Equity | 0.60 % | |||
| Current Ratio | 1.40 X | |||
| Book Value Per Share | 89.51 X | |||
| Cash Flow From Operations | 5.06 B | |||
| Earnings Per Share | 1.22 X | |||
| Price To Earnings To Growth | 2.52 X | |||
| Number Of Employees | 47.06 K | |||
| Beta | 0.33 | |||
| Market Capitalization | 9.2 B | |||
| Total Asset | 163.44 B | |||
| Retained Earnings | 14.62 B | |||
| Working Capital | 19.59 B | |||
| Current Asset | 61.39 B | |||
| Current Liabilities | 41.8 B | |||
| Z Score | 1.6 | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 3.15 % | |||
| Net Asset | 163.44 B | |||
| Last Dividend Paid | 0.42 |
About Shanghai Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Shanghai Pink Sheet Analysis
When running Shanghai Pharmaceuticals' price analysis, check to measure Shanghai Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shanghai Pharmaceuticals is operating at the current time. Most of Shanghai Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Shanghai Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shanghai Pharmaceuticals' price. Additionally, you may evaluate how the addition of Shanghai Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.